Gynecologic Oncology

Article	Citations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	203
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery	90
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125	86
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	85
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	80
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	76
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials	73
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes	73
Redefining readmissions in gynecologic cancer: readmissions resulting in hospital-to-hospice transitions may represent high value care	72
Sentinel lymph node procedures in endometrial cancer: an international multicenter experience	70
Stage IV gynecologic cancers patients who subsequently died from disease: lessons learned from their health care journey	63
The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter	61
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	56
Outcomes of splenectomy during primary cytoreductive surgery in ovarian cancer	53
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	53
Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer	52
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)	51
Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice	51
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)	51
Perioperative outcomes in obese women with uterine cancer	51
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)	51
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	50
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)	48
Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia	47
Impact of surgeon type and rurality on treatment and survival of ovarian cancer patients	46

Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)	45
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)	44
Determining the optimal adjuvant therapy strategy in uterine leiomyosarcoma	43
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)	43
Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer	43
Comparison of solid tumor mutations under the targeted agent and profiling utilization registry (TAPUR) study: how do gynecologic cancers compare with others?	42
Disparities in access to high volume surgeons within high volume hospitals for hysterectomy	41
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)	41
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)	41
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)	41
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)	40
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer	40
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce	39
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)	39
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)	38
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)	37
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)	37
Assessing somatic mutations in matched biospecimens from patients with serous ovarian cancer	37
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)	36
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)	36
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)	36
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)	36
Quality of oncologic care and outcomes of patients with endometrial cancer managed at minority-serving hospitals	35
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)	35
Comprehensive genomic profiling (CGP) via peripheral blood liquid biopsies identifies therapeutically relevant genomic alterations in tubo-ovarian and peritoneal cancer	35
Uptake and outcomes of sentinel lymph node mapping in women with atypical endometrial hyperplasia	34
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)	34
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)	34
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)	34
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)	34
Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic	34
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	33
Professional fulfillment and burnout among physicians at a large NCI-designated Comprehensive Cancer Center	33
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis	33
Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021,	32
Workplace bullying, harassment and microaggressions: the results of a Women of Gynecologic Oncology (WGO) survey	32
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor	31
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC)	31
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program	31
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial	31
The clinical utility of the Khorana score in determining risk for venous thromboembolism in patients with gynecologic cancer	31
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma	30
Publication trends focused on palliative and end-of-life care for gynecologic malignancies	30
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement	30
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group	30
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial	30
Disparities in ovarian cancer treatment and overall survival according to race: An update	29
Profiling the immune landscape in mucinous ovarian carcinoma	29
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903	29
Defining “enlarged” sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?	29

Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer	29
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer	29
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations	29
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo	28
Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284)	28
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study	28
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)	28
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer	28
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial	27
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study	27
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs	27
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas	27
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies	27
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	27
RE1 transcription factor is decreased in endometrial cancer	27
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility	27
Uterine cancer among Asian Americans: Disparities & clinical characteristics and disease presentations	27
Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high-grade serous ovarian carcinoma	26
Peritoneal washing analysis in endometrial cancer: Does somatic mutation detection with panel sequencing build upon traditional cytologic analysis?	26
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study	26
Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology cli	26
The outcome of waiting for radiotherapy in locally advanced cervical cancer	25
The Doc versus the Bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology	25
What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?	25
COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer	25
The use of pedometers to assess patient ambulation following gynecologic oncology surgery: A prospective observational study	25
Themes, perspectives, and educational quality of content related to Pap smears on TikTok and YouTube	25
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	25
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	25
The implementation of an electronic symptom management system to monitor the severity of symptoms in gynecologic oncology patients initiating chemotherapy: A multicenter evaluation	25
Oncologic outcomes and adverse events with immunotherapy treatment among frail patients with gynecologic cancers	24
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices	24
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends	24
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III tria	24
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	24
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer	24
Accuracy of patient-reported gynecologic cancer diagnoses and procedures at a large academic medical center	24
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis	24
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study	24
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials	23
CRABP2 – A novel biomarker for high-risk endometrial cancer	23
Editorial board	23
Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)	23
Neuroendocrine tumors of the gynecologic tract update	23
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer	23
Novel therapy in endometrial cancer: How much will we pay?	23
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer	23
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study fr	23
Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review	23
Cervical Cancer Disparities in the American Indian/Alaska Native Population: Are Prevention Tools Being Utilized? (108)	23
Utilizing the KELIM score and the chemo-response score to predict chemosensitivity in ovarian cancer (1212)	22
Platinum refractory advanced stage ovarian clear cell carcinoma: time to reconsider primary therapy?	22
Analyses of DNA repair protein expression in BRCA1 mutant patient-derived xenografts	22
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative	22
Endometrial cancer recurrence after the use of an intrauterine manipulator during laparoscopic surgery: A retrospective cohort study (1216)	22
Obesity-related cancers disproportionately affect women compared to men in the United States (399)	22
Obesity-driven microbial and metabolic changes with cytotoxic chemotherapy in the LKB1fl/flp53fl/fl genetically engineered mouse model of endometrioid endometrial cancer	22
Editorial board	22
Editorial board	22
Thoracic epidural analgesia in Gynecologic Oncology ERAS: A waste of time or time to consider it as a standard of care? (2162)	22
Social precarity as a novel framework for addressing psychosocial needs of patients with gynecologic cancers (2227)	21
Distinct T cell receptor diversity and integrative analyses of clinically defined high-grade serous ovarian cancer	21
Sentinel lymph node biopsy compared with systematic lymphadenectomy in patients with uterine carcinosarcoma (536)	21
Utility of lymphadenectomy in mucinous ovarian carcinoma	21
The rising incidence of sex cord stromal ovarian tumors in the US: Who is most at risk? (442)	21
Lived experience of women diagnosed with a gynecologic cancer in the height of the COVID-19 pandemic in New York City (508)	21
Frequency of homologous recombination associated gene mutations in Japanese patients with ovarian cancer	21
Geographic disparities in the United States gynecologic oncology workforce: Cancer care inequities and the paradox of more docs (014)	21
Foreword	21
Characterization and comparison of pelvic mass risk assessment by gynecologists and PCPs to ROMA	21
Telemedicine patient satisfaction metrics and methods of recurrence detection for gynecologic cancer patients throughout the initial year of the COVID-19 pandemic (515)	21
Effect of treatment sequence on mortality in advanced-stage endometrial cancer	21
Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium (029)	21
The impact of abortion restrictions on pregnant individuals with cancer in the United States: A statistical model (013)	21
Silencing ROR2 inhibits metastatic behavior of ovarian cancer cells	20
Eliminating racial disparities in endometrial cancer clinical trial enrollment in the Deep South: a pathway to equity	20
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study	20
Response to Letter to the Editor, Gilks et al.	20
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies	20
Surgical universal euglycemic attainment during recovery (SUGAR) initiative: Sweet results through quality improvement (286)	20

Molecular targets and prognosis for uterine cancer: What is the role of mutations of unknown significance? (1262)	20
Early detection of endometrial cancer	20
Transcriptomic immune profiling: a precision path forward for immunotherapy in patients with cervical cancer?	20
The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial	19
Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes	19
Response to Alexandre Andre B A da Costa et al.	19
Frequency of actionable germline mutations identified through tumor next generation sequencing in a gynecologic cancer cohort (394)	19
Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study	19
Widening cancer care disparities in the adoption of telemedicine during COVID 19: who is left behind?	19
Postoperative management and outcomes before and after closure of a women's health specialty unit at a tertiary care facility	19
Co-expression of PD-L1 and DDR2 in cervical cancer	19
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist	19
Variation in cervical cancer screening test utilization and results in a United States-based program	19
Phase II trial of eribulin in advanced/recurrent cervical cancer	19
Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab f	19
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma	19
Investigation of perturbation of DNMT and TET enzymes in endometrial cancer (308)	19
Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (LBA 5)	19
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning	19
From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?	19
Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies	19
Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovari	19
Health care services burden in ovarian cancer patients receiving PARP inhibitor maintenance treatment (377)	19
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification	19
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328	18
An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial	18
Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan	18
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/	18
Gamma secretase inhibitors, in combination with cytotoxic agents, decrease migration and invasion of uterine leiomyosarcoma	18
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA	18
TERT promoter mutations and gene amplification in endometrial cancer	18
Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therapy	18
Characteristics and factors associated with mortality among cervical cancer patients undergoing palliative care	18
Disease progression, survival, and molecular disparities among Black and White patients with endometrioid endometrial carcinoma in real-world registries and legacy NRG oncology phase III trials	18
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants	18
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression	18
Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study	18
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia rece	18
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global,	18
Cancer center case volume is associated with differences in the effectiveness of neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer	18
Assessing the readability of online health information regarding treatment modalities for gynecologic cancer patients	17
Frailty does not completely explain racial disparities in postoperative outcomes after ovarian cancer debulking	17
Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells	17
Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings:	17
Patterns of recurrence and outcomes in vulvar extramammary Paget's disease	17
Financial toxicity among gynecologic oncology surgical patients	17
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer	17
3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer	17
Progression-free and overall survival of sequential platinum, taxane, and bevacizumab followed by immunotherapy may be equivalent to concurrent chemotherapy and immunotherapy among patients with recur	17
Feasibility of laparoscopic visceral-peritoneal debulking among patients with stage III–IV ovarian cancer: The ULTRA-LAP Pilot Trial	17
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer	17
Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)	16
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center	16
Increasing serum gamma-glutamyltransferase level accompanies a rapid increase in the incidence of endometrial cancer in Korea: A nationwide cohort study	16
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis	16
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Nor	16
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic	16
Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival	16
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review	16
Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer	16
Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists	16
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081	16
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwa	16
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification	16
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	16
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	16
Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis	15
Evaluating nutrition in advanced ovarian cancer: which biomarker works best?	15
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer	15
Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy	15
Cervical adenocarcinoma: Factors and outcomes in early-stage patients	15
Local treatment improves survival in patients with stage IVB cervical cancer	15
Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?	15
Editorial Board	15
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu	15
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis	15
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial	15
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival	15
Practice patterns and clinical outcomes in women with gynecologic malignancies who refuse blood products	15
The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer	15
Prognosis and conditional survival among women with newly diagnosed ovarian cancer	15
Functional and psychosocial quality of life in gynecologic Cancer survivors with and without lymphedema symptoms	15
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapy	15
Utility of germline multi-gene panel testing in patients with endometrial cancer	15
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPE	15
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer	15
Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database	15
Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure	15
Screening for endometrial disease: Analyzing risk factors for abnormal endometrial pathology in a high-risk population	14
Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study	14
Factors influencing gynecologic risk reduction surgeries for BRCA1 or BRCA2 germline mutation carriers	14
Implementation of automated social determinants of health screening in gynecologic oncology: A pilot study	14
The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer	14
Impact of COVID-19 on missed diagnoses of uterine cancer: Who is most affected?	14
Characteristics of mismatch repair deficient endometrial cancer in a diverse cohort	14